The present invention is related to Nox4 inhibitors pharmaceutical composition thereof and to their use for the treatment and/or prevention of osteoporosis or an osteoclastogenesis dysfunction in particular osteoporotic and pre osteoporotic osteoclastogenesis dysfunction.